SEC Comment Letter 0000000000-22-013543 to Vor Biopharma Inc. (VOR)
Vor Biopharma Inc.
Date: Dec. 15, 2022 · CIK: 0001817229 · Accession: 0000000000-22-013543
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268798
Letter
United States securities and exchange commission logo December 15, 2022 Robert Ang, M.B.B.S. President and Chief Executive Officer Vor Biopharma Inc. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140 Re:Vor Biopharma Inc. Registration Statement on Form S-3 Filed December 14, 2022 File No. 333-268798 Dear Robert Ang: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Divakar Gupta
Show Raw Text
United States securities and exchange commission logo
December 15, 2022
Robert Ang, M.B.B.S.
President and Chief Executive Officer
Vor Biopharma Inc.
100 Cambridgepark Drive, Suite 101
Cambridge, MA 02140
Re:Vor Biopharma Inc.
Registration Statement on Form S-3
Filed December 14, 2022
File No. 333-268798
Dear Robert Ang:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Divakar Gupta